Guanidine derivatives and their use as neuropeptide FF receptor antagonists

US7727979B2 · kind B2 · utility

Assignee

• Actelion Pharmaceuticals Ltd. · CH

Inventors

• Eva Caroff · Allschwil, CH
• Matthias Steger · Zürich, CH
• Oliver Valdenaire · Allschwil, CH
• Anja Fecher · Allschwil, CH
• Volker Breu · Schliengen, DE
• Kurt Hilpert · Therwil, CH
• Heinz Fretz · Riehen, CH
• Thomas Giller · Wintersingen, CH

Key dates

• Filing date: Mar 22, 2004
• Grant date: Jun 1, 2010
• Expiry date: Jul 24, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by —N(R′)— or —O— and R′ is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I), comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence. The above can be produced using generally used methods and processed to give medicaments.